The Effect of Time to Treatment on Outcome in Very Elderly Thrombolysed Stroke Patients

Background Intravenous thrombolysis is beneficial in, even very elderly, acute ischemic stroke patients. However, while the relation between treatment benefit and treatment delay (onset time to treatment) in patients younger than 80 years is well known, it is uncertain in the very elderly. Aims This analysis aims at examining this relationship in the elderly, and to provide a comparison with the derived relationship in younger patients as a check of validity. Methods We assessed the interaction between age, onset time to treatment, and thrombolysis exposure by analyzing the modified Rankin scale score distribution or mortality rate at 90 days, among patients registered in a trials archive. We established whether the effect of alteplase changes with onset time to treatment, by treating onset time to treatment as a continuum in a multivariate logistic regression model. Results Data were available for 3063 patients, of whom 2341 were thrombolysed. Five hundred ninety-seven patients were aged >80, of whom 352 were thrombolysed. Among patients aged >80, no significant interaction of outcome with onset time to treatment was observed (P = 0·4650), but the estimated slope of the decay in benefit with onset time to treatment was comparable with that established for younger patients. Analyzing the entire dataset, there was an interaction between onset time to treatment and alteplase treatment (P = 0·0159), but neither between age and onset time to treatment (P = 0·7098) nor between age and alteplase treatment (P = 0·0755). Conclusions In this nonrandomized comparison, the relationship of benefit and safety with thrombolysis across onset time to treatment in very elderly stroke patients was comparable with that in their younger counterparts. Across the investigated time span of 3·5 h, we can safely treat with the same time window as we use for younger patients.

[1]  W R Clarke,et al.  Baseline NIH Stroke Scale score strongly predicts outcome after stroke , 1999, Neurology.

[2]  D. Tanné,et al.  Predictors of good outcome after intravenous tPA for acute ischemic stroke , 2001, Neurology.

[3]  Peter C Austin,et al.  Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? , 2003, American heart journal.

[4]  I. White,et al.  Assessing subgroup effects with binary data: can the use of different effect measures lead to different conclusions? , 2005, BMC medical research methodology.

[5]  J. Grotta,et al.  The Virtual International Stroke Trials Archive , 2007, Stroke.

[6]  A. Ziegler,et al.  Predicting Long-Term Outcome After Acute Ischemic Stroke , 2008 .

[7]  Christian Weimar,et al.  Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials , 2008, Stroke.

[8]  B. Ovbiagele,et al.  Prevention and management of stroke in very elderly patients , 2009, The Lancet Neurology.

[9]  J. Grotta,et al.  Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity: A Comparison of Outcomes in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.

[10]  Elsa Azevedo,et al.  Intravenous Alteplase for Stroke in Those Older Than 80 Years Old , 2010, Stroke.

[11]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[12]  H. Diener,et al.  Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.

[13]  A. Rabinstein,et al.  Collateral Flow Predicts Response to Endovascular Therapy for Acute Ischemic Stroke , 2011 .

[14]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[15]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[16]  A. Sergeant Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive , 2013 .